In yet another boost to several large drugmakers, the FDA has agreed with European regulators there is no existing evidence to confirm recent concerns that a widely used group of diabetes drugs called GLP-1 inhibitors is linked to pancreatic cancer, an FDA spokeswoman says.

Read more